

1 **Ultrarare Variants in DNA Damage Repair Genes in Pediatric Acute-Onset**
2 **Neuropsychiatric Syndrome or Acute Behavioral Regression in Neurodevelopmental**
3 **Disorders**

4
5 **Running title: DNA Damage Repair Genes in Acute Behavioral Regression**

6
7 Janet L. Cunningham¹, Jennifer Frankovich², Robert A. Dubin³, Erika Pedrosa⁴, Refia Nur
8 Baykara⁴, Noelle Cathleen Schlenk⁵, Shahina B. Maqbool⁶, Hedwig Dolstra⁴, Jacqueline
9 Marino⁴, Jacob Edinger⁴, Julia M. Shea⁴, Gonzalo Laje⁷, Sigrid M.A. Swagemakers⁸, Siamala
10 Sinnadurai^{8,9}, Peter J. van der Spek⁸, Herbert M. Lachman^{10*}

11
12 ¹Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden

13
14 ²Department of Pediatrics, Division of Pediatric Allergy, Immunology, Rheumatology and
15 Immune Behavioral Health Program, Stanford Children's Health and Stanford University School
16 of Medicine, Palo Alto, CA, USA

17 ³Center for Epigenomics / Computational Genomics Core, Albert Einstein College of Medicine

18 ⁴Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine.

19 ⁵Stanford Children's Health, PANS Clinic and Research Program, Stanford University School of
20 Medicine, Stanford, CA, USA.

21 ⁶Department of Genetics Epigenetics Shared Facility, Albert Einstein College of Medicine

22 ⁷Department of Psychiatry, Permian Basin, Texas Tech University Health Sciences Center
23 School of Medicine

24 ⁸Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, Netherlands

25 ⁹Department of Epidemiology and Health Promotion at the School of Public Health
26 Medical Center for Postgraduate Education, Warsaw, Poland

27 ¹⁰Department of Psychiatry and Behavioral Sciences, Department of Medicine, Department of
28 Genetics, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of
29 Medicine

31 *corresponding author
32 Dr. Herbert Lachman
33 Albert Einstein College of Medicine
34 Forchheimer 103
35 1300 Morris Park Ave.
36 Bronx, New York 10461
37 Phone: 718-430-2428
38 Email: Herb.Lachman@einsteinmed.edu
39
40

41 **Abstract**

42 Acute onset of severe psychiatric symptoms or regression may occur in children with premorbid
43 neurodevelopmental disorders, although typically developing children can also be affected.
44 Infections or other stressors are likely triggers. The underlying causes are unclear, but a current
45 hypothesis suggests the convergence of genes that influence neuronal and immunological
46 function. We previously identified 11 genes in Pediatric Acute-Onset Neuropsychiatry Syndrome
47 (PANS), in which two classes of genes related to either synaptic function or the immune system
48 were found. Among the latter, three affect the DNA damage response (DDR): *PPM1D*, *CHK2*,
49 and *RAG1*. We now report an additional 16 cases with mutations in *PPM1D* and other DDR
50 genes in patients with acute onset of psychiatric symptoms and/or regression that were
51 classified by their clinicians as PANS or another inflammatory brain condition. The genes
52 include clusters affecting p53 DNA repair (*PPM1D*, *ATM*, *ATR*, *53BP1*, and *RMRP*), and the
53 Fanconi Anemia Complex (*FANCE*, *SLX4/FANCP*, *FANCA*, and *FANCI*). We hypothesize that
54 defects in DNA repair genes, in the context of infection or other stressors, could lead to an
55 increase in cytosolic DNA in immune cells triggering DNA sensors, such as cGAS-STING and
56 AIM2 inflammasomes. These findings could lead to new treatment strategies.

57

58 **Introduction**

59 We recently reported the first whole exome and whole genome sequencing (WES and
60 WGS, respectively) analysis in Pediatric Acute-Onset Neuropsychiatry Syndrome (PANS) in
61 which ultrarare variants were found in 11 genes in 21 cases¹. The genes harboring ultrarare
62 variants (minor allele frequency <0.001) showed extensive heterogeneity but clustered to those
63 that affect innate and adaptive immunity; *PPM1D* (3 cases), *NLRC4* (4 cases), *RAG1* (3 cases),
64 *PLCG2*, and *CHK2*, or genes that affect synaptic function; *SGCE* (2 cases), *CACNA1B* (2
65 cases), *SHANK3* (3 cases), and one case each for *GRIN2A*, *GABRG2*, and *SYNGAP1*. Of the
66 21 subjects, five were diagnosed with autism spectrum disorder (ASD) before their deterioration
67 that met PANS criteria. In addition to ASD, four cases were diagnosed with another
68 neurodevelopmental disorder (NDD), one of whom had Jansen de Vries Syndrome (JdVS),
69 which is caused by truncating mutations in *PPM1D* exons 5 or 6 that cause a gain-of-function
70 effect by suppressing p53 and other proteins involved in the DNA damage repair response
71 (DDR) (e.g., *MDM2*, *ATM*, *CHK1*, *CHK2*, *ATR*, and *H2AX*)²⁻⁶. The high prevalence of PANS
72 superimposed on pre-existing NDD is consistent with the observations of other groups^{7, 8}.

73 PANS is thought to be an inflammatory disorder that primarily affects the deep brain grey
74 matter (primarily the basal ganglia but the thalamus and amygdala may be involved in more

75 extensive cases). This hypothesis is based on the cardinal symptoms of PANS and is supported
76 by four neuroimaging studies showing the following: swelling of the basal ganglia during the
77 acute stage, microglial activation in the caudate and globus pallidus, grey/white matter
78 differences in the basal ganglia, and microstructural changes throughout the brain but most
79 prominently in the basal ganglia⁹⁻¹².

80 The clinical diagnosis PANS has core symptoms of abrupt onset obsessive-compulsive
81 disorder (OCD) and/or restricted eating (food aversion), with two or more secondary symptoms:
82 anxiety, emotional lability, irritability, rage, cognitive regression, sleep disturbance, sensory
83 dysregulation, movement abnormalities, urinary symptoms including new onset dysuria or
84 urinary frequency¹³. While the criteria require 2 secondary symptoms, most patients have 5 to 6
85 secondary symptoms that start abruptly alongside the OCD and/or eating restriction. Autonomic
86 instability (POTS, dilated pupils, increased urinary frequency, enuresis) and hypermobility have
87 also been reported as co-morbid with PANS¹³⁻¹⁸. A deterioration in school performance occurs,
88 exemplified by the loss of previously learned skills and/or new onset procedural learning
89 challenges presumably relating to the basal ganglia inflammation PANS^{9-12, 19}. Activities of daily
90 living, extracurricular activities, and social interactions are severely affected during relapses.
91 PANS can occur in children with or without premorbid ASD or other NDD.

92 For parents, the abrupt onset is a telling feature with a rapid decline in behavior and
93 functioning that is sometimes, literally, overnight or emerging over a period of a week. The
94 course is typically relapsing and remitting, but not all relapses are hyperacute/acute. Relapses
95 are frequently associated with an infection and data in support of a neuroinflammatory etiology
96 for PANS is accumulating. In the subgroup of cases following Streptococcus infections, a range
97 of group A streptococcal (GAS) autoantibodies and antibodies to striatal cholinergic
98 interneurons can be detected^{15, 20-22}. Recently, an increased prevalence of folate receptor alpha
99 autoantibodies associated with cerebral folate deficiency and ASD were detected in PANS²³.
100 Additionally, cross-sectional prevalence data show that approximately one-third of patients
101 meeting PANS criteria eventually develop enthesitis-related arthritis (ERA) and/or inflammatory
102 back pain further supporting a role for inflammation in this disorder^{18, 24}. Furthermore,
103 inflammatory/autoimmune disorders are prevalent in first-degree family members^{8, 25, 26}.

104 As is true in other rare pediatric rheumatological conditions (including ERA and
105 Sydenham chorea), observational studies in PANS suggest that non-steroidal anti-inflammatory
106 drugs (NSAIDs) and corticosteroids may alleviate symptoms and/or shorten the length of the
107 relapses²⁷⁻²⁹. More potent immunomodulators, such as intravenous immunoglobulin (IVIg) and a

108 B-cell inhibitor Rituximab have mixed results, likely due to the genetic heterogeneity and the
109 difficulty in appropriately powering randomized trials in relapsing/remitting conditions^{30, 31}.

110 An immune-based etiology is also suggested in some cases of ASD and NDD,
111 especially acute and subacute regression, which have some symptoms that overlap with PANS
112 and respond to immunomodulators³²⁻³⁵. In addition, a strong family history of autoimmune
113 disorders is associated with an increased risk for ASD³⁶⁻³⁸.

114 We are interested in identifying genetic factors that underlie the development of PANS
115 and acute behavioral regression using next-generation sequencing. In our original paper, two of
116 the ultrarare variants we found are in genes that affect DDR (*PPM1D* and *CHK2*), and one
117 induces DNA breaks (*RAG1*). *RAG1*, along with *RAG2*, codes for endonucleases that induce
118 DNA double-strand breaks responsible for the somatic recombination that generates immune
119 cell diversity in B- and T-lymphocytes^{1, 39, 40}. *RAG1/RAG2* also affects NK cell differentiation and
120 plays a role in DNA transposition^{41, 42}. Double-stranded breaks induced by the RAG complex are
121 repaired by ATM, a serine/threonine kinase that orchestrates DNA repair at double-strand
122 breaks^{40, 43-45}.

123 Our overarching aim is to identify genetic variations that converge on common biological
124 pathways within the heterogeneous population of children with PANS or acute-onset regression
125 with or without premorbid NDD. Given the findings in our first PANS genetic study, one common
126 pathway is DNA repair. This hypothesis is supported by the findings in this paper in which many
127 other genes involved in DNA repair were identified that may contribute to genetic vulnerability.

128

129 **Subjects and Methods**

130 **Ethical considerations**

131 This study was conducted in accordance with the Declaration of Helsinki. Parents signed
132 informed consent approved by the Albert Einstein College of Medicine IRB (2022-14636).

133

134 **Subjects.** The subjects were identified through connections between the senior investigators
135 and a PANS group called EXPAND, a non-profit European advocacy organization for families of
136 children, adolescents, and adults with immune-mediated neuropsychiatric disorders
137 (<https://expand.care/>), through the Neuroimmune Foundation, a non-profit organization
138 dedicated to neuroimmune and inflammatory brain conditions (<https://neuroimmune.org/about/>),
139 The Louisa Adelynn Johnson Fund for Complex Disease
140 (<https://tlajfundforcomplexdisease.com/>), and the Jansen de Vries Syndrome Foundation
141 (<https://jansen-devries.org/>). Histories were obtained by the participating physicians and

142 confirmed and collated by one of the senior investigators who interviewed every family member
143 (H.M.L). The cases met the criteria for PANS with or without co-morbid ASD or NDD, or
144 individuals with ASD or other NDDs who had a history of rapid-onset behavioral regression.

145

146 **Genetic analyses**

147 Whole exome sequencing (WES) data was available for six cases (**Table**). WES was carried out
148 by different companies Courtagen Diagnostics Laboratory, GeneDx, Baylor Genetics, and for
149 case 10, WES was conducted locally in the Genetics Core at the Albert Einstein College of
150 Medicine, Epigenetics Shared Facility. For the remaining cases, data was available from
151 commercially available panels: Invitae (Primary Immunodeficiency Panel), NHS North West
152 (NDD panel). The genetic variants for cases 1 and 4-12 were verified using Sanger sequencing
153 (see **Table** and **Supplementary Methods**). A comprehensive description of the library
154 preparation and analysis of sequencing data for the Einstein sample (case 10) can be found in
155 the **Supplementary Methods** section. Parents were genotyped for variants found in all cases
156 except cases 10, and 13-16.

157

158 **Evaluation of Variants**

159 Minor allele frequencies (MAFs) were obtained from the GnomAD database on the UCSC
160 Genome Browser (<https://genome.ucsc.edu/>). The ClinVar database, Combined Annotation-
161 Dependent Depletion (CADD), and AlphaMissense were used to predict the pathogenicity of
162 mutations⁴⁶⁻⁴⁹. <https://www.ncbi.nlm.nih.gov/clinvar/>. RNAfold was used to predict the secondary
163 structure of RMRP. A detailed explanation is in the **Supplementary Methods** section.

164

165 **Results**

166 Ultrarare variants (MAF <0.001) affecting DNA repair genes were found in 16 cases (10 males
167 and 6 females; specific sex of cases not included to maintain anonymity) including four families
168 with two or more affected individuals. The identified genes are involved in the p53 repair
169 pathway: *PPM1D* (2 cases), *ATM* (5 cases), *ATR* (2 cases), and *53BP1* (one case) (**Figure 1**),
170 and the Fanconi Anemia Complex (FC): *FANCF* (2 cases), *FANCP/SLX4* (2 cases), *FANCI*,
171 and *FANCA* (one case each) (**Figure 2**; see **Table** for details on all p53 and FC gene variants).
172 The FC pathway repairs DNA interstrand crosslinks and interacts with ATM/ATR/p53 DNA
173 repair pathways (**Figure 2**)⁵⁰⁻⁵⁵. In addition, ultrarare variants were found in 32 other genes,
174 many of which have effects on DNA repair and innate immune function (see **Supplementary**
175 **Table** for details on all additional variants for this and other cases described in this paper).

176 STRING was used to show the connections between the DNA repair genes and other variants
177 found in this study, which centered around ATM and p53 (**Figure 3**). The cases and genetic
178 variants with their potential impact on the phenotypes are described below.

179

180 **p53 DNA Repair Pathway (*PPM1D*, *ATM*, *ATR*, *53BP1*)**

181 **PPM1D (Protein phosphatase, Mg²⁺/Mn²⁺-dependent 1D)**

182 Case 1 has JdVS with a 1:1 mosaicism for a de novo truncating *PPM1D* variant in exon 6. The
183 patient was diagnosed with mild intellectual disability but was high functioning, requiring minimal
184 support until high school when the patient had an abrupt onset of OCD, anxiety, cognitive
185 regression, insomnia, and psychosis with rapid decline over approximately three weeks. The
186 deterioration coincided with an upper respiratory infection and vasculitis. Further regression
187 occurred with the loss of previously mastered global abilities and eventual development of
188 mutism, which has persisted for several years, unresponsive to psychiatric medications and
189 other clinical and behavioral interventions.

190 Two additional ultrarare de novo variants were found and are likely pathogenic, one of
191 which is relevant to the DDR hypothesis: a variant in *CSNK1a1*, which codes for Casein Kinase
192 1 Alpha 1, a p53 inhibitor^{56, 57}. Another was found in *SRPK3*, an SRSF Protein Kinase that has
193 no known effect on DDR, although interestingly, expression is inversely correlated with alpha-
194 synuclein levels in mouse models of Parkinson's disease⁵⁸. Finally, an inherited ultrarare,
195 nonsense mutation was found in the citrate transporter, *SLC13A5* as well as a splice acceptor
196 variant in *CACNA1S*.

197 Case 2 also has a typical JdVS variant (a truncating mutation in *PPM1D* exon 6) and
198 was diagnosed with ASD and a learning disability. The patient has periods of abrupt onset
199 behavioral regression lasting several days to months, characterized by eating refusal, rage,
200 cognitive deficits, loss of previously learned skills, an inability to walk, and enuresis. The most
201 severe relapses have occurred following infection with SARS-CoV2 and a Group A
202 Streptococcal infection concurrent with shingles.

203

204 **ATM (Ataxia-telangiectasia mutated or serine/threonine kinase)**

205 Case 3 carries an ultrarare and pathological frameshift mutation in *ATM*. The patient was
206 typically developing and excelled in school until adolescence when diagnosed with Postural
207 Orthostatic Tachycardia Syndrome (POTS), irritable bowel syndrome gastroparesis, and
208 enthesitis-related arthritis. Soon thereafter, an episode of gastroenteritis led to acute-onset
209 OCD, anxiety, impulsivity, and severe rage; the first of many such episodes. An MRI scan was

210 negative. Relapses responded to IVIg and steroid bursts; however, due to frequent relapses and
211 the development of chronic symptoms, a trial of Rituximab was undertaken, which was helpful.
212 While the patient appeared to respond to immunomodulation, severe symptoms returned when
213 these therapies were tapered or discontinued. Multiple hospitalizations for uncontrolled
214 psychiatric symptoms followed. A parent carries the same ATM variant and has a history of
215 dysautonomia and an inflammatory skin conditions.

216 Other ultrarare variants found in this patient include a de novo variant in *AHNAK2* and
217 compound heterozygosity for two ultrarare *CACNA1H* variants. While there are no obvious
218 connections to DNA repair, *AHNAK2* has been implicated in systemic lupus erythematosus
219 (SLE) in two studies and *CACNA1H* mutations are found in ASD and intellectual disabilities⁵⁹⁻⁶².

220 Cases 4-7 are a family with four affected children who all carry a pathogenic parental
221 transmitted ATM splice donor mutation. There is a bilneal parental history of severe autoimmune
222 disorders and hypermobile joints, as well as an extended family history of early-onset cancer,
223 and autoimmune disorders. This is consistent with the increased risk of cancer and autoimmune
224 disorders in individuals with loss of function mutations in *ATM*⁶³⁻⁶⁶.

225 Case 4, the proband, was diagnosed with ASD and experienced a typical PANS
226 relapsing-remitting course with abrupt relapses of OCD, food aversion, anxiety, irritability,
227 impulse control problems, oppositional behaviors, tics, and fatigue. Relapses were commonly
228 coincident with infections and were effectively managed by addressing infections with antibiotics
229 and using IVIg. The proband also has a history of Hashimoto's thyroiditis, joint hypermobility,
230 and consistently low immunoglobulin levels which likely contributed to frequent infections.
231 Alongside the *ATM* variant, the patient inherited rare and ultrarare variants affecting DNA repair
232 and innate immunity including a likely pathogenic variant in *RNASEH2B*, which codes for
233 Ribonuclease H2, an enzyme that removes ribonucleotides that have been incorporated into
234 replicating DNA, affecting double-stranded break repair kinetics⁶⁷. Homozygosity for this variant
235 leads to Aicardi-Goutières syndrome (AGS), a type I interferonopathy characterized by
236 neurodevelopmental defects and upregulation of type I interferon signaling and
237 neuroinflammation due to the effects of DNA damage^{67, 68}. The patient also has ultrarare
238 nonsynonymous variants of unknown significance in *RAG2*, *NOD2*, and a 24-base pair
239 microduplication in *SP110*. Each of these genes has effects on innate immunity, but *RAG2* is the
240 only one with a strong connection to DNA repair, as described in the introduction^{1, 39, 40, 69}. An
241 *NOD2* variant was transmitted from one of the parents. A second ultrarare variant in *NOD2* was
242 identified in the other parent (see **Supplementary Table**).

243 Cases 5-7 are siblings to case 4 who were all diagnosed with ASD, dysautonomia, and
244 joint hypermobility. They all have a relapsing-remitting course characterized by abrupt onset
245 OCD, anxiety, emotional lability, increased urinary frequency, oppositional behavior, and
246 reduced social interactions, along with cognitive and behavioral regression. Relapses are
247 typically coincident with infection. Case 5 had an MRI that showed right temporal sclerosis.
248 Cases 6 and 7 have epilepsy, low levels of IgM and IgA, and relapses improve after clearance
249 of infection and treatment with IVIg and/or a corticosteroid burst. Although they were not
250 analyzed by WES, each was analyzed by Sanger sequencing for the variants found in the
251 proband. Each sibling has inherited the *ATM* variant, and cases 5 and 6, the *RNASEH2B*
252 variant. They have also inherited one of the two *NOD2* variants.

253

254 **ATR (Ataxia telangiectasia and rad3-related protein)**

255 Cases 8 and 9 are siblings with regressive ASD and a relapsing-remitting course with relapses
256 commonly coincident with infections. They both have a unique, transmitted ultrarare *ATR* variant
257 of unknown significance. One parent has a history of Hashimoto's thyroiditis and a family history
258 of SLE, and the other parent has a history of joint hypermobility and childhood seizure disorder.
259 *ATR* is a serine/threonine kinase and DNA damage sensor that functions as a master regulator
260 of the DDR⁷⁰⁻⁷⁴. The proband, case 8, was a typically developing child with hypermobility who
261 was well until abrupt behavioral regression occurred following "croup" at which time a diagnosis
262 of ASD was made. The patient subsequently developed a relapsing-remitting course
263 characterized by abrupt onset OCD, aggression, and mutism. Relapses appeared to be
264 responsive to NSAIDs.

265 The proband's sibling, Case 9, was well until the development of an abrupt behavioral
266 regression and loss of previously achieved milestones following a herpesvirus 6 infection, after
267 which a diagnosis of ASD was made. The patient also has a relapsing-remitting course
268 characterized by abrupt onset of OCD, restricted eating, rage, and depression. Relapses are
269 typically coincident with infections. Symptoms typically respond to glucocorticoid bursts. MRI
270 showed atrophy of the hippocampus, amygdala, caudate, and putamen. WES analysis of both
271 cases 8 and 9 also revealed several other ultrarare variants of interest: *NLRX1*, *CENPJ*,
272 *CACNA1S*, *DBH*, and *CLPB*. The most interesting from the DNA repair perspective is a
273 pathogenic frameshift mutation in *CENPJ*, which codes for centromere protein J. Centromere
274 regulation is critical for maintaining genomic stability, and defects lead to aberrant mitosis and
275 activation of the cGAS-STING pathway^{74, 75}. It is interesting to note that biallelic mutations in
276 *CENPJ* and *ATR* can both cause Seckel syndrome, which is associated with cell-cycle

277 checkpoint signaling abnormalities^{76, 77}. Another variant was found in *NLRX1*, which codes for a
278 key player in the innate immune response that regulates NF- κ B expression and has been
279 implicated in autoimmune and inflammatory diseases⁷⁸⁻⁸¹. A third sibling is typically developing
280 and did not inherit the *ATR* variant but carries the *CENPJ*, *CACNA1S*, and *CLPB* variants.
281 Thus, the two affected siblings with ASD and acute-onset neuropsychiatric symptoms have
282 ultrarare variants in two genes that affect DNA repair, *ATR*, and *CENPJ*, as well as *NLRX1*
283 *DBH*, *CACNA1S*, and *CLPB*.

284

285 **53BP1 (Tumor suppressor p53-binding protein 1)**

286 Case 10 has a history of developmental delay, and experienced severe regression as a young
287 child characterized by loss of the ability to walk, loss of verbal skills, and new-onset enuresis.
288 Upon WES, we found an ultrarare missense mutation in *53BP1*, a p53-binding protein that
289 regulates DDR⁸²⁻⁸⁴. A preceding infection to initial deterioration was not ascertainable.
290 However, the patient developed a relapsing-remitting course with relapses (abrupt onset of
291 OCD, eating refusal, severe rage, and oppositional behavior) coincident with infections with
292 improvement following treatment infections with antibiotics. The patient also developed
293 Hashimoto's thyroiditis, scoliosis, joint hypermobility, and gastroparesis. A parent has a history
294 of Raynaud's and fibromyalgia, and there is a family history of thyroid disease and Parkinson's
295 Disease. Parents have not been genotyped. In addition to *53BP1*, several other ultrarare
296 variants were found that could be playing a role in the clinical state via DNA repair. One is
297 *MED1*, which codes for a mediator complex protein that plays a major role in homologous
298 recombination, base excision repair, the maintenance of genomic stability, and p53-dependant
299 apoptosis⁸⁵. It has also been implicated in SLE⁸⁶. Another is *KMT2D*, which codes for a histone
300 methyltransferase that plays a role in DNA repair and has been implicated in autoimmune
301 disorders^{87, 88}. Finally, we found a nonsense mutation in *MTO1*, which regulates oxidative
302 phosphorylation and has been found to affect DNA repair and recombination in yeast^{89, 90}.

303

304 **Fanconi Anemia Complex (FANCE, FANCP/SLX4, FANCA, and FANCI)**

305 **FANCE (Fanconi anemia complementation group E)**

306 Cases 11 and 12, a sibling pair with common variable immune deficiency (CVID) and acute
307 onset of neuropsychiatric symptoms; both carry an ultrarare missense mutation in *FANCE*.
308 Case 11 met the diagnostic criteria for PANS, characterized by a relapsing-remitting course of
309 abrupt onset OCD, anxiety, and rage. Episodes were commonly coincident with group A
310 streptococcal infection and other infections and always improved after treating the infection

311 followed by a corticosteroid burst. IVIg (aimed to treat the underlying CVID) was associated with
312 a reduced frequency of relapses but did not reduce the severity of relapses. Case 12 was
313 diagnosed with ASD as a child after the abrupt loss of speech and eye contact following an
314 infection. The patient regained eye contact and sociability, but apraxia of speech continued. He
315 regressed again later in childhood and soon thereafter was diagnosed with PANS characterized
316 by abrupt onset of OCD, anxiety, aggression (self-injurious behavior and property destruction),
317 and tics, which improved after treating the infection followed by corticosteroids. The patient
318 subsequently developed acute onset dysarthria and mutism and further evaluation revealed
319 CSF pleocytosis, intracranial hypertension, and GAD antibodies (three times the upper limit of
320 normal). Subsequent relapses responded to addressing infection followed by a corticosteroid
321 burst. Relapse frequency (but not severity) was reduced following the introduction of IVIg to
322 treat CVID. Due to a chronic progressive course, Rituximab was added, which was followed by
323 documented improvements by the speech pathologist that were lost when B cells were
324 repopulated (the speech pathologist was blinded to treatments and B cell repopulation).
325 Consequently, Rituximab was scheduled quarterly. The clinical trajectory improved but
326 deteriorations coincident with infections occurred, so Leflunomide was added as adjunct therapy
327 which has led to further stabilization for 2 years. There is a positive history of an inflammatory
328 skin disease on both sides of the family and a family history of an immunodeficiency syndrome,
329 arthritis, lupus-related autoantibodies, recurrent sepsis, and recurrent septic joints. Both cases
330 carry an ultrarare variant of unknown significance in *VPS13B*. Case 11 carries a maternally
331 transmitted *NOD2* variant that has been described as a risk allele in Crohn's disease^{90, 91}. Case
332 12 carries another ultrarare, pathogenic, novel variant involved in the DNA repair gene,
333 *THRAP3*, which codes for thyroid hormone receptor-associated protein 3, an RNA processing
334 factor involved in ATR kinase-dependent DDR and the expression of several DNA repair
335 proteins, including FANCL^{92, 93}.

336

337 **FANCI (Fanconi anemia, complementation group I)**

338 Case 13 is a neurotypical child who developed a sudden onset of OCD, fatigue, restricted
339 eating, severe anxiety, enuresis, and insomnia following an upper respiratory infection.
340 Autoimmune thyroiditis was diagnosed based on having high titers of anti-thyroid peroxidase
341 and anti-thyroglobulin antibodies, an elevated TSH, and an ultrasound. A nonsense mutation in
342 *FANCI* was identified. There was a partial response to intravenous glucocorticoids, IVIg, and
343 Rituximab. Case 11 also carries ultrarare variants in two other genes that affect DNA repair.
344 One is a non-synonymous variant in another FC gene, *FANCP/SLX4*, which may be a benign

345 variant. However, cases 14 and 15 also have an ultrarare variant in this gene (see below). The
346 other is a variant in the DNA repair gene, *LIG4*, which codes for DNA Ligase IV, a key enzyme
347 involved in repairing DNA double-strand breaks through non-homologous end joining and
348 sealing DNA breaks that occur during V(D)J recombination^{94, 95}. *LIG4* mutations cause
349 autoimmune and immunodeficiency disorders^{95, 96}.

350

351 **FANCP/SLX4 Fanconi anemia, complementation group P/Structure-Specific** 352 **endonuclease subunit)**

353 Cases 14 and 15 are siblings diagnosed with CVID who carry a pathogenic mutation in
354 *TNFRSF13B*, which is one of the more common variants found in immune deficiencies^{97, 98}. The
355 same variant has been found in several other PANS cases (unpublished observations). They
356 also share an ultrarare variant in *FANCP/SLX4*, but the relatively low CADD score suggests that
357 the gene alone is not sufficient to explain the severe clinical presentation. Case 14 has a history
358 of acute neuropsychiatric decompensation consistent with PANS, who initially responded to
359 treatment with corticosteroid bursts and IVIg and further stabilized on Anakinra. Case 15 initially
360 presented with anxiety but has regressed substantially, developing a seizure disorder and
361 autoimmune encephalitis (AE) that has partially responded to Rituximab, glucocorticoids, and
362 IVIg. Anakinra has not been effective. MRI indicates atrophy. The siblings also have an ultrarare
363 missense mutation adjacent to a splice acceptor site in *DOCK8*, which has been implicated in
364 immune deficiency and autoimmune disorders^{65, 99}. Both also share a variant in *MEFV* (pyrin),
365 an inflammasome regulator gene that is commonly mutated in autoinflammatory disorders¹⁰⁰⁻¹⁰³.
366 Finally, they both have an ultrarare variant in *RMRP*, a noncoding RNA that functions as the
367 RNA component of mitochondrial RNA processing endoribonuclease. This is a very intriguing
368 candidate according to our DNA repair model as it acts as an inhibitor of p53^{104, 105}. A
369 comparison between wild-type and mutant alleles using RNAfold shows differences in the
370 secondary structure, suggesting that it could be functional (**Supplementary Figure**).

371

372 **FANCA Fanconi Anemia, Complementation Group A**

373 Case 16 is a previously healthy and neurotypical child who presented with abrupt-onset OCD,
374 eating restriction, severe irritability, hyperactivity, aggression, mood swings, sensory
375 amplification, and headaches. Physical exams showed truncal instability, subtle choreiform
376 movements, folliculitis, and findings consistent with enthesitis and arthritis (confirmed on joint
377 ultrasound). Labs indicate persistently elevated vasculitis markers (high vWF Ag and D-dimers
378 after COVID-19), persistently elevated C4, and persistent microcytic anemia thought to be

379 secondary to chronic inflammation. The patient has had a secondary progressive course with
380 relapses coincident with infections (influenza, mycoplasma, COVID-19, and sinusitis) with partial
381 improvement after bacterial infections were treated. Psychotropics and CBT have been
382 minimally helpful. The patient did not tolerate oral or IV steroids, IVIG, or immunomodulation
383 aimed at treating arthritis and systemic inflammation (e.g., methotrexate, sulfasalazine, and
384 azathioprine). There has been a partial response to NSAIDs, and more recently, a solid
385 trajectory of improvement since introducing colchicine. An ultrarare pathogenic variant
386 (according to AlphaMissense) was found in *FANCA*. In addition, ultrarare variants were found in
387 five other genes that have effects on innate immune function, but no direct effect on DNA repair.
388 The most important is a pathogenic variant in *UNC93B1*, a regulator of nucleic acid-sensing toll-
389 like receptors (e.g., TLR3, TLR7, and TLR8) and interferon and STING signaling, suggesting a
390 synergistic interaction with *FANCA*-related DNA repair defects¹⁰⁶⁻¹⁰⁸. The others are ultrarare
391 variants of unknown significance in *NLRP1*, *TICAM1*, *TYK2*, and *TCN2*. *NLRP1*, *TICAM1*, and
392 *TYK2* have regulatory effects on the innate immune system, including nucleic acid sensing, and
393 have been implicated in autoimmune disorders¹⁰⁹⁻¹¹².

394 First-degree relatives have migraines, recurrent sinusitis, recurrent pancreatitis, and
395 spondylarthritis. First-degree family members also have anxiety, OCD, ADHD, and depression.
396

397 **Discussion**

398 Sixteen cases were identified with ultrarare variants in protein-coding genes related to p53 and
399 FC DNA repair pathways: *PPM1D*, *ATM*, *ATR*, *53BP1*, *FANCE*, *FANCI*, *FANCP/SLX4*, and
400 *FANCA*. These were often accompanied by additional rare variants related to DNA repair and/or
401 immune deficiencies. Most individuals in this study have an underlying neurodevelopmental
402 disorder, with approximately half diagnosed with ASD. The unifying feature for these cases is
403 the distinct, acute onset change in behavior, severe psychiatric symptoms, and loss of function
404 in association with infections and other stressors. Many cases have symptoms consistent with
405 PANS, while others had acute, severe neuropsychiatric decompensation (e.g., mutism,
406 behavioral regression, loss of previously learned skills, cognitive dysfunction) that did not meet
407 clinical criteria for PANS. Co-morbid inflammatory conditions were common, including vasculitis
408 signs (n=2), enthesitis and/or arthritis (n=3), thyroiditis, and/or elevated thyroid antibodies (n=3).
409 Inflammatory conditions were also common among first-degree family members. Three cases
410 had abnormal MRI scans (cases 5, 9, and 15), and one (case 3) had a normal study.
411 Pleocytosis and moderately elevated anti-GAD antibodies were found in case 12. Clinical
412 improvement was observed in most cases following the resolution of infections and the

413 application of immunomodulation (NSAIDs, corticosteroids, IVIg, Rituximab, colchicine, etc.).
414 The findings are congruent with our previous work and provide further support for our
415 hypothesis that DNA repair deficits are a vulnerability factor for neuropsychiatric
416 decompensation.

417 The DNA repair hypothesis first emerged from our original genetic analysis in which
418 three out of the five immune genes we identified have strong connections to this process:
419 *PPM1D*, *CHK2*, and *RAG1*¹. The idea that DNA repair deficits underlie PANS and acute
420 decompensation in NDD is novel, although studies linking DDR to behavior have been
421 described. For example, postmitotic genome instability in neurons can lead to behavioral
422 alterations and neurodegenerative disorders, and genetic studies show that DNA repair genes
423 are involved in genetic subgroups of ASD and NDDs including most of the genes described in
424 this report (e.g., *PPM1D*, *ATM*, *ATR*, *53BP1*, *FANCE*, *FANCI*, and *FANCP/SLX4*)¹¹³⁻¹²⁰.

425 The two major gene families affecting DNA repair described in this paper code for
426 proteins involved in the p53 and FC pathways. So far, between the current study and our
427 previous report, we have found ultrarare variants in five protein-coding genes that directly affect
428 p53: *PPM1D*, *ATM*, *CHK2*, *ATR*, and *53BP1*. Among these genes, pathogenic mutations were
429 found in *PPM1D*, *ATM*, and, in our previous study, *CHK2*. The ultrarare *ATR* and *53BP1*
430 variants described in this paper, however, are variants of unknown significance that will require
431 replication and functional validation. Remarkably, we also found an ultrarare variant in the long
432 non-coding RNA gene, *RMRP*, a p53 inhibitor^{104, 105}. *RMRP* expression is induced by immune
433 activators and is increased in autoimmune/autoinflammatory disorders¹²¹. As described in the
434 results section, structural differences between the mutant and wild-type alleles were predicted
435 by RNAfold, but again, functional validation would be needed to determine whether the *RMRP*
436 variant we identified affects p53 function and DNA repair.

437 Ultrarare variants were found in four different FC genes: *FANCE*, *FANCP/SLX4*, *FANCI*,
438 and *FANCA*. Among these, all are predicted to be pathogenic, except the *FANCP/SLX4*
439 variants. However, the fact that two different ultrarare variants were found in this gene in three
440 cases from two families increases the likelihood they are playing a role. Interestingly, FC
441 proteins interact with components of the p53 DDR pathway, including *ATM* and *ATR* (**Figure**
442 **2**)¹²²⁻¹²⁵.

443 Some researchers have suggested that autoimmune and/or autoinflammatory processes
444 underlie the development of behavioral regression in PANS and in a subgroup of individuals
445 with ASD^{35, 126-128}. Impaired DDR may be one mechanism for these associations as it can lead to
446 leakage of nuclear DNA into the cytosol, which can trigger the cGAS-STING pathway, a key

447 component of the type I interferon (IFN-I) anti-viral innate immune response, especially following
448 an infectious disease trigger^{66, 129-131}. Mitochondrial DNA breaks and oxidized mitochondrial DNA
449 released into the cytosol can also trigger cGAS-STING¹³²⁻¹³⁴. AIM2 inflammasome signaling,
450 which leads to the induction of IL-1 β and IL-18, is also triggered by cytosolic DNA^{135, 136}.

451 Physiological activation of cGAS-STING is central for the response to foreign viral DNA,
452 and perhaps viral RNA as well⁴¹. However, studies show that over-activation can lead to
453 autoimmune, autoinflammatory, and neurodegenerative disorders¹³⁷⁻¹⁴⁰. For example, increased
454 IFN-I responses mediated by cGAS-STING due to abnormal clearance of cytosolic DNA and
455 RNA have been implicated in the pathogenesis of autoimmune disorders including SLE and
456 aggressive rheumatoid arthritis¹⁴¹⁻¹⁴⁴. Circulating type I IFN levels are elevated in approximately
457 50% of patients with SLE and IFN receptor inhibition is an approved therapy^{145, 146}. A substantial
458 fraction of SLE patients have neuropsychiatric symptoms^{147, 148}. It has also been proposed that
459 some neurodegenerative disorders involve cGAS-STING signaling, including Alzheimer's
460 Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's
461 disease (HD), and multiple sclerosis (MS)¹⁴⁹⁻¹⁵¹. Markers for neurodegenerative disorders are
462 elevated in 27% of patients with psychiatric disease preselected for suspected immunological
463 involvement and phenotypes including catatonia, agitation, and acute onset of symptoms similar
464 to the cases described here, although the genetic data is not available
465 (<https://doi.org/10.21203/rs.3.rs-3491787/v1>). Early immunological interventions may mitigate
466 some damage, but this needs to be confirmed in clinical trials. However, other forms of damage
467 may accumulate over time that are not responsive to immunological interventions.

468 In addition to nuclear DNA, disruption of mitochondrial integrity can also lead to the
469 release of mitochondrial DNA into the cytoplasm, which is a potent cGAS-STING trigger¹³²⁻¹³⁴. A
470 few of the genes described in this report have effects on mitochondria (e.g., *MTO1*, *SLC13A5*,
471 *RMRP*). Some FC proteins also regulate mitochondrial DNA replication fork stability that can
472 activate the mtDNA-dependent cGAS/STING response when dysfunctional, and FANCI has
473 been found to regulate PRKN-mediated mitophagy^{152, 153}.

474 A large number of cases had more than one DNA repair gene mutation. This could be
475 due to ascertainment bias since most of the cases we studied had severe symptoms and
476 accompanying neurodevelopmental problems, which could have prompted genetic testing by
477 their physicians. Gene panels rather than WGS per se were performed in many cases, which
478 could cause ascertainment bias due to the selection of genes represented on the commercially
479 available gene panels (**Table**). However, the histories of autoimmune disorders from both
480 parents in many cases suggest true bilineal inheritance of risk variants.

481 The current paper explores a genetic subgroup linked to impaired DNA repair with acute
482 onset of severe psychiatric symptoms or regression in children associated with infections. It is
483 important to note that non-infectious cellular stressors can also induce DNA damage and
484 activate cGAS-STING, such as cellular injury, heat shock, and oxidative stress^{154, 155}. In
485 addition, recent studies suggest that faulty DNA repair could disrupt several cellular processes
486 beyond an innate immune response, such as autophagy, senescence, and apoptosis¹⁵⁶⁻¹⁵⁸.

487 Clinically, if our findings are confirmed, they could lead to specific diagnostic tools and
488 new treatments for infection-associated psychiatric episodes and behavioral decompensation in
489 PANS, ASD, and other NDDs in those with DNA repair mutations, targeting putative over-
490 stimulated immune pathways (e.g., type I interferons and AIM2 inflammasomes). To validate our
491 findings, more studies are needed to integrate longitudinal clinical data, genetics, and
492 immunophenotypes. Functional studies on immune cells from patients, and microglia from
493 animal models and induced pluripotent stem cells (iPSCs) are also needed. Studies using iPSC-
494 derived microglia with genetic variants in DNA repair genes are ongoing.

495 References

- 496 1. Trifiletti, R. *et al.* Identification of ultra-rare genetic variants in pediatric acute onset
497 neuropsychiatric syndrome (PANS) by exome and whole genome sequencing. *Sci. Rep.* **12**,
498 11106-3 (2022).
- 499 2. Bhattacharya, D., Hiregange, D. & Rao, B. J. ATR kinase regulates its attenuation via PPM1D
500 phosphatase recruitment to chromatin during recovery from DNA replication stress signalling. *J.*
501 *Biosci.* **43**, 25-47 (2018).
- 502 3. Jansen, S. *et al.* De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D
503 Cause an Intellectual Disability Syndrome. *Am. J. Hum. Genet.* **100**, 650-658 (2017).
- 504 4. Gräf, J. F. *et al.* Substrate spectrum of PPM1D in the cellular response to DNA double-strand
505 breaks. *iScience* **25**, 104892 (2022).
- 506 5. Nahta, R. & Castellino, R. C. Phosphatase magnesium-dependent 1 δ (PPM1D),
507 serine/threonine protein phosphatase and novel pharmacological target in cancer. *Biochem.*
508 *Pharmacol.* **184**, 114362 (2021).
- 509 6. Zekavat, S. M. *et al.* TP53-mediated clonal hematopoiesis confers increased risk for incident
510 atherosclerotic disease. *Nat. Cardiovasc. Res.* **2**, 144-158 (2023).
- 511 7. Jyonouchi, H., Geng, L. & Davidow, A. L. Cytokine profiles by peripheral blood monocytes are
512 associated with changes in behavioral symptoms following immune insults in a subset of ASD
513 subjects: an inflammatory subtype? *J. Neuroinflammation* **11**, 187-2 (2014).

- 514 8. O'Dor, S. L. *et al.* A Survey of Demographics, Symptom Course, Family History, and Barriers
515 to Treatment in Children with Pediatric Acute-Onset Neuropsychiatric Disorders and Pediatric
516 Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections. *J. Child*
517 *Adolesc. Psychopharmacol.* **32**, 476-487 (2022).
- 518 9. Giedd, J. N., Rapoport, J. L., Garvey, M. A., Perlmutter, S. & Swedo, S. E. MRI assessment
519 of children with obsessive-compulsive disorder or tics associated with streptococcal infection.
520 *Am. J. Psychiatry* **157**, 281-283 (2000).
- 521 10. Kumar, A., Williams, M. T. & Chugani, H. T. Evaluation of basal ganglia and thalamic
522 inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with
523 streptococcal infection and tourette syndrome: a positron emission tomographic (PET) study
524 using ¹¹C-[R]-PK11195. *J. Child Neurol.* **30**, 749-756 (2015).
- 525 11. Cabrera, B. *et al.* Neuroanatomical features and its usefulness in classification of patients
526 with PANDAS. *CNS Spectr.* **24**, 533-543 (2019).
- 527 12. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
528 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
529 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).
- 530 13. Chang, K. *et al.* Clinical evaluation of youth with pediatric acute-onset neuropsychiatric
531 syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. *J. Child*
532 *Adolesc. Psychopharmacol.* **25**, 3-13 (2015).
- 533 14. Vreeland, A. *et al.* Neuroinflammation in Obsessive-Compulsive Disorder: Sydenham
534 Chorea, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal
535 Infections, and Pediatric Acute Onset Neuropsychiatric Syndrome. *Psychiatr. Clin. North Am.*
536 **46**, 69-88 (2023).
- 537 15. Vreeland, A. *et al.* Post-infectious inflammation, autoimmunity, and OCD: Sydenham
538 Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
539 infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Disorder (PANS). *Dev.*
540 *Neurosci.* (2023).
- 541 16. Thienemann, M. *et al.* Clinical Management of Pediatric Acute-Onset Neuropsychiatric
542 Syndrome: Part I-Psychiatric and Behavioral Interventions. *J. Child Adolesc. Psychopharmacol.*
543 **27**, 566-573 (2017).
- 544 17. Chan, A. *et al.* Children With PANS May Manifest POTS. *Front. Neurol.* **13**, 819636 (2022).
- 545 18. Ma, M. *et al.* Arthritis in children with psychiatric deteriorations: a case series. *Dev.*
546 *Neurosci.*, 1 (2023).
- 547 19. Foerde, K. & Shohamy, D. The role of the basal ganglia in learning and memory: insight
548 from Parkinson's disease. *Neurobiol. Learn. Mem.* **96**, 624-636 (2011).

- 549 20. Swedo, S. E. *et al.* Pediatric autoimmune neuropsychiatric disorders associated with
550 streptococcal infections: clinical description of the first 50 cases. *Am. J. Psychiatry* **155**, 264-271
551 (1998).
- 552 21. Cunningham, M. W. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive
553 Antigens of Group A Streptococci and their Sequelae. *Microbiol. Spectr.* **7**,
554 10.1128/microbiolspec.GPP3-2018 (2019).
- 555 22. Hyman, S. E. PANDAS: Too Narrow a View of the Neuroimmune Landscape. *Am. J.*
556 *Psychiatry* **178**, 5-7 (2021).
- 557 23. Wells, L., O'Hara, N., Frye, R. E., Hullavard, N. & Smith, E. Folate Receptor Alpha
558 Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric
559 Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
560 Population. *Journal of personalized medicine* **14**, 166 (2024).
- 561 24. Frankovich, J. *et al.* Multidisciplinary clinic dedicated to treating youth with pediatric acute-
562 onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients.
563 *J. Child Adolesc. Psychopharmacol.* **25**, 38-47 (2015).
- 564 25. Masterson, E. E. & Gavin, J. M. Baseline characteristics of children in the International
565 PANS Registry (IPR) Epidemiology Study. *BMJ Open* **14**, e072743-072743 (2024).
- 566 26. Chan, A. *et al.* Familial Clustering of Immune-Mediated Diseases in Children with Abrupt-
567 Onset Obsessive Compulsive Disorder. *J. Child Adolesc. Psychopharmacol.* **30**, 345-346
568 (2020).
- 569 27. Brown, K. *et al.* Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral
570 Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based
571 PANS Clinic. *J. Child Adolesc. Psychopharmacol.* **27**, 629-639 (2017).
- 572 28. Brown, K. D. *et al.* Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on
573 Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of
574 Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric
575 Syndrome Clinic. *J. Child Adolesc. Psychopharmacol.* **27**, 619-628 (2017).
- 576 29. Spartz, E. J. *et al.* Course of Neuropsychiatric Symptoms After Introduction and Removal of
577 Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study. *J. Child Adolesc.*
578 *Psychopharmacol.* **27**, 652-659 (2017).
- 579 30. Perlmutter, S. J. *et al.* Therapeutic plasma exchange and intravenous immunoglobulin for
580 obsessive-compulsive disorder and tic disorders in childhood. *Lancet* **354**, 1153-1158 (1999).
- 581 31. Williams, K. A. *et al.* Randomized, Controlled Trial of Intravenous Immunoglobulin for
582 Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J.*
583 *Am. Acad. Child Adolesc. Psychiatry* **55**, 860-867.e2 (2016).

- 584 32. Hart, S. J., Worley, G., Kishnani, P. S. & Van Mater, H. Case Report: Improvement
585 Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative
586 Disorder. *Front. Neurol.* **12**, 621637 (2021).
- 587 33. Bey, A. L. *et al.* Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations
588 Responds to Immunomodulation. *Pediatrics* **145**, e20191490. doi: 10.1542/peds.2019-1490
589 (2020).
- 590 34. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
591 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
592 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).
- 593 35. Malek, M. *et al.* Prednisolone as Adjunctive Treatment to Risperidone in Children With
594 Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. *Clin.*
595 *Neuropharmacol.* **43**, 39-45 (2020).
- 596 36. Mohebalizadeh, M. *et al.* Role of Maternal Immune Factors in Neuroimmunology of Brain
597 Development. *Mol. Neurobiol.* (2023).
- 598 37. Croen, L. A. *et al.* Family history of immune conditions and autism spectrum and
599 developmental disorders: Findings from the study to explore early development. *Autism Res.*
600 **12**, 123-135 (2019).
- 601 38. Arenella, M. *et al.* Immunogenetics of autism spectrum disorder: A systematic literature
602 review. *Brain Behav. Immun.* **114**, 488-499 (2023).
- 603 39. Braams, M., Pike-Overzet, K. & Staal, F. J. T. The recombinase activating genes: architects
604 of immune diversity during lymphocyte development. *Front. Immunol.* **14**, 1210818 (2023).
- 605 40. Christie, S. M., Fijen, C. & Rothenberg, E. V(D)J Recombination: Recent Insights in
606 Formation of the Recombinase Complex and Recruitment of DNA Repair Machinery. *Front.*
607 *Cell. Dev. Biol.* **10**, 886718 (2022).
- 608 41. Ni, G., Ma, Z. & Damania, B. cGAS and STING: At the intersection of DNA and RNA virus-
609 sensing networks. *PLoS Pathog.* **14**, e1007148 (2018).
- 610 42. Chen, X. *et al.* How mouse RAG recombinase avoids DNA transposition. *Nat. Struct. Mol.*
611 *Biol.* **27**, 127-133 (2020).
- 612 43. Helmink, B. A. & Sleckman, B. P. The response to and repair of RAG-mediated DNA
613 double-strand breaks. *Annu. Rev. Immunol.* **30**, 175-202 (2012).
- 614 44. Johnston, R. *et al.* Nuclease-independent functions of RAG1 direct distinct DNA damage
615 responses in B cells. *EMBO Rep.*, e55429 (2022).
- 616 45. Chu, S. H. *et al.* Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination
617 during Lymphoid Development. *iScience* **23**, 100941 (2020).

- 618 46. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
619 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886-D894
620 (2019).
- 621 47. Niroula, A. & Vihinen, M. How good are pathogenicity predictors in detecting benign
622 variants? *PLoS Comput. Biol.* **15**, e1006481 (2019).
- 623 48. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human
624 genetic variants. *Nat. Genet.* **46**, 310-315 (2014).
- 625 49. Cheng, J. *et al.* Accurate proteome-wide missense variant effect prediction with
626 AlphaMissense. *Science* **381**, eadg7492 (2023).
- 627 50. Ceccaldi, R., Sarangi, P. & D'Andrea, A. D. The Fanconi anaemia pathway: new players and
628 new functions. *Nat. Rev. Mol. Cell Biol.* **17**, 337-349 (2016).
- 629 51. Jones, M. J. K. & Huang, T. T. The Fanconi anemia pathway in replication stress and DNA
630 crosslink repair. *Cell Mol. Life Sci.* **69**, 3963-3974 (2012).
- 631 52. Traband, E. L. *et al.* Mitotic DNA Synthesis in Untransformed Human Cells Preserves
632 Common Fragile Site Stability via a FANCD2-Driven Mechanism That Requires HELQ. *J. Mol.*
633 *Biol.* **435**, 168294 (2023).
- 634 53. Bona, N. & Crossan, G. P. Fanconi anemia DNA crosslink repair factors protect against
635 LINE-1 retrotransposition during mouse development. *Nat. Struct. Mol. Biol.* (2023).
- 636 54. Kupculak, M. *et al.* Phosphorylation by ATR triggers FANCD2 chromatin loading and
637 activates the Fanconi anemia pathway. *Cell. Rep.* **42**, 112721 (2023).
- 638 55. Alcón, P. *et al.* FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of
639 FANCD2 during DNA repair. *Nat. Struct. Mol. Biol.* **27**, 240-248 (2020).
- 640 56. Xu, W. *et al.* Casein kinase 1 α inhibits p53 downstream of MDM2-mediated autophagy and
641 apoptosis in acute myeloid leukemia. *Oncol. Rep.* **44**, 1895-1904 (2020).
- 642 57. Liu, X. *et al.* Tumor-derived CK1 α mutations enhance MDMX inhibition of p53. *Oncogene*
643 **39**, 176-186 (2020).
- 644 58. Seo, M. H. & Yeo, S. Association Between Decreased Srpk3 Expression and Increased
645 Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson's Disease Mouse
646 Model. *Mol. Neurobiol.* **60**, 780-788 (2023).
- 647 59. Akizuki, S. *et al.* PLD4 is a genetic determinant to systemic lupus erythematosus and
648 involved in murine autoimmune phenotypes. *Ann. Rheum. Dis.* **78**, 509-518 (2019).
- 649 60. Wen, L. *et al.* Exome-wide association study identifies four novel loci for systemic lupus
650 erythematosus in Han Chinese population. *Ann. Rheum. Dis.* **77**, 417-211823. Epub 2017 Dec
651 12 (2018).

- 652 61. Kessi, M. *et al.* Calcium channelopathies and intellectual disability: a systematic review.
653 *Orphanet J. Rare Dis.* **16**, 219-0 (2021).
- 654 62. Viggiano, M. *et al.* Contribution of CACNA1H Variants in Autism Spectrum Disorder
655 Susceptibility. *Front. Psychiatry.* **13**, 858238 (2022).
- 656 63. Woodward, E. R. *et al.* Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC
657 in 1514 triple negative familial and isolated breast cancers from a single centre, with extended
658 testing of ATM, RAD51C and RAD51D in over 400. *J. Med. Genet.* (2023).
- 659 64. Stubbins, R. J., Korotev, S. & Godley, L. A. Germline CHEK2 and ATM Variants in Myeloid
660 and Other Hematopoietic Malignancies. *Curr. Hematol. Malign Rep.* **17**, 94-104 (2022).
- 661 65. Azizi, G. *et al.* The Autoimmune Manifestations in Patients with Genetic Defects in the B Cell
662 Development and Differentiation Stages. *J. Clin. Immunol.* **43**, 819-834 (2023).
- 663 66. Pezone, A. *et al.* Inflammation and DNA damage: cause, effect or both. *Nat. Rev.*
664 *Rheumatol.* **19**, 200-211 (2023).
- 665 67. Ghosh, D., Kumari, S. & Raghavan, S. C. Depletion of RNASEH2 Activity Leads to
666 Accumulation of DNA Double-strand Breaks and Reduced Cellular Survivability in T Cell
667 Leukemia. *J. Mol. Biol.* **434**, 167617 (2022).
- 668 68. Viguera-Elías, D., de la Iglesia-Nagore, I., Toledo-Gotor, C., Domínguez-Garrido, E. & Poch-
669 Olivé, M. L. Aicardi-Goutieres syndrome: a family case due to alteration of the RNASEH2B
670 gene. *Rev. Neurol.* **72**, 407-409 (2021).
- 671 69. Walia, J. & Mujahid, R. Clinical Disease States Related to Mutations of the NOD2 Gene: A
672 Case Report and Literature Review. *Cureus* **15**, e38584 (2023).
- 673 70. Priya, B., Ravi, S. & Kirubakaran, S. Targeting ATM and ATR for cancer therapeutics:
674 Inhibitors in clinic. *Drug Discov. Today* **28**, 103662 (2023).
- 675 71. Maréchal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. *Cold Spring*
676 *Harb Perspect. Biol.* **5**, a012716. doi: 10.1101/cshperspect.a012716 (2013).
- 677 72. Saxena, S. & Zou, L. Hallmarks of DNA replication stress. *Mol. Cell* **82**, 2298-2314 (2022).
- 678 73. Paull, T. T. Mechanisms of ATM Activation. *Annu. Rev. Biochem.* **84**, 711-738 (2015).
- 679 74. Lee, J. & Paull, T. T. Activation and regulation of ATM kinase activity in response to DNA
680 double-strand breaks. *Oncogene* **26**, 7741-7748 (2007).
- 681 75. Huang, Y. *et al.* DNAJA2 deficiency activates cGAS-STING pathway via the induction of
682 aberrant mitosis and chromosome instability. *Nat. Commun.* **14**, 5246-0 (2023).
- 683 76. Brown, A. D. *et al.* ATR suppresses endogenous DNA damage and allows completion of
684 homologous recombination repair. *PLoS One* **9**, e91222 (2014).

- 685 77. McIntyre, R. E. *et al.* Disruption of mouse Cenpj, a regulator of centriole biogenesis,
686 phenocopies Seckel syndrome. *PLoS Genet.* **8**, e1003022 (2012).
- 687 78. Nagai-Singer, M. A., Morrison, H. A. & Allen, I. C. NLRX1 Is a Multifaceted and Enigmatic
688 Regulator of Immune System Function. *Front. Immunol.* **10**, 2419 (2019).
- 689 79. Chen, L., Cao, S., Lin, Z., He, S. & Zuo, J. NOD-like receptors in autoimmune diseases.
690 *Acta Pharmacol. Sin.* **42**, 1742-1756 (2021).
- 691 80. Liu, M. *et al.* The regulatory role of NLRX1 in innate immunity and human disease. *Cytokine*
692 **160**, 156055 (2022).
- 693 81. Chu, X., Wu, S. & Raju, R. NLRX1 Regulation Following Acute Mitochondrial Injury. *Front.*
694 *Immunol.* **10**, 2431 (2019).
- 695 82. Leriche, M. *et al.* 53BP1 interacts with the RNA primer from Okazaki fragments to support
696 their processing during unperturbed DNA replication. *Cell. Rep.* **42**, 113412 (2023).
- 697 83. Arnould, C. *et al.* Chromatin compartmentalization regulates the response to DNA damage.
698 *Nature* **623**, 183-192 (2023).
- 699 84. Vincendeau, E. *et al.* SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but
700 critical for productive class switch recombination. *Nat. Commun.* **13**, 3707-3 (2022).
- 701 85. Honjoh, H. *et al.* MED1, a novel binding partner of BRCA1, regulates homologous
702 recombination and R-loop processing. *Sci. Rep.* **12**, 17140-8 (2022).
- 703 86. Armstrong, D. L. *et al.* GWAS identifies novel SLE susceptibility genes and explains the
704 association of the HLA region. *Genes Immun.* **15**, 347-354 (2014).
- 705 87. Adam, M. P., Hudgins, L. & Hannibal, M. in *GeneReviews*(®) (ed Adam, M. P. et al.)
706 (University of Washington, Seattle. GeneReviews is a registered trademark of the University of
707 Washington, Seattle. All rights reserved, Seattle (WA), 1993).
- 708 88. Dermawan, J. K. *et al.* Distinct genomic landscapes in radiation-associated angiosarcoma
709 compared with other radiation-associated sarcoma histologies. *J. Pathol.* **260**, 465-477 (2023).
- 710 89. Zhurinsky, J. *et al.* Effects of the microtubule nucleator Mto1 on chromosomal movement,
711 DNA repair, and sister chromatid cohesion in fission yeast. *Mol. Biol. Cell* **30**, 2695-2708 (2019).
- 712 90. Zhou, C. *et al.* Clinical and genetic analysis of combined oxidative phosphorylation
713 deficiency-10 caused by MTO1 mutation. *Clin. Chim. Acta* **526**, 74-80 (2022).
- 714 91. Mushtaq Hashim Al-Bdere, N., Faaz Nassir Al-Saad, N., Jawad Al-Imari, M., Mudhafer
715 Habbeeb, S. & Mizal Azoz, A. Genetic Polymorphisms of NOD2 and ATG16L1 in Different Types
716 of Digestive Tract Inflammation. *Arch. Razi Inst.* **78**, 493-498 (2023).

- 717 92. Vohhodina, J. *et al.* The RNA processing factors THRAP3 and BCLAF1 promote the DNA
718 damage response through selective mRNA splicing and nuclear export. *Nucleic Acids Res.* **45**,
719 12816-12833 (2017).
- 720 93. Beli, P. *et al.* Proteomic investigations reveal a role for RNA processing factor THRAP3 in
721 the DNA damage response. *Mol. Cell* **46**, 212-225 (2012).
- 722 94. Kumari, N., Antil, H., Kumari, S. & Raghavan, S. C. Deficiency of ligase IV leads to reduced
723 NHEJ, accumulation of DNA damage, and can sensitize cells to cancer therapeutics. *Genomics*
724 **115**, 110731 (2023).
- 725 95. Jauch, A. J. *et al.* Autoimmunity and immunodeficiency associated with monoallelic LIG4
726 mutations via haploinsufficiency. *J. Allergy Clin. Immunol.* **152**, 500-516 (2023).
- 727 96. Yilmaz Demirdag, Y. & Gupta, S. Infections in DNA Repair Defects. *Pathogens* **12**, 440. doi:
728 10.3390/pathogens12030440 (2023).
- 729 97. Ramirez, N. *et al.* Multi-omics analysis of naïve B cells of patients harboring the C104R
730 mutation in TACI. *Front. Immunol.* **13**, 938240 (2022).
- 731 98. Kakkas, I. *et al.* TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in
732 Greece. *Medicina (Kaunas)* **57**, 827. doi: 10.3390/medicina57080827 (2021).
- 733 99. de Valles-Ibáñez, G. *et al.* Evaluating the Genetics of Common Variable Immunodeficiency:
734 Monogenetic Model and Beyond. *Front. Immunol.* **9**, 636 (2018).
- 735 100. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
736 autoinflammatory diseases. *Front. Immunol.* **14**, 1265404 (2023).
- 737 101. Karamanakos, A. *et al.* Autoinflammatory syndromes with coexisting variants in
738 Mediterranean FeVer and other genes: Utility of multiple gene screening and the possible
739 impact of gene dosage. *Semin. Arthritis Rheum.* **56**, 152055 (2022).
- 740 102. Wouters, F., Bogie, J., Wullaert, A. & van der Hilst, J. Recent Insights in Pyrin
741 Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-
742 Associated Autoinflammatory Syndromes. *J. Clin. Immunol.* **44**, 8-5 (2023).
- 743 103. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
744 autoinflammatory diseases. *Front. Immunol.* **14**, 1265404 (2023).
- 745 104. Hao, Q., Lu, H. & Zhou, X. A potential synthetic lethal strategy with PARP inhibitors:
746 perspective on 'Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP'. *J. Mol.*
747 *Cell. Biol.* **13**, 690-692 (2021).
- 748 105. Huang, R. *et al.* The p53/RMRP/miR122 signaling loop promotes epithelial-mesenchymal
749 transition during the development of silica-induced lung fibrosis by activating the notch pathway.
750 *Chemosphere* **263**, 128133 (2021).

- 751 106. Wolf, C. *et al.* UNC93B1 variants underlie TLR7-dependent autoimmunity. *Sci. Immunol.*,
752 eadi9769 (2024).
- 753 107. He, Z., Ye, S., Xing, Y., Jiu, Y. & Zhong, J. UNC93B1 curbs cytosolic DNA signaling by
754 promoting STING degradation. *Eur. J. Immunol.* **51**, 1672-1685 (2021).
- 755 108. Zhu, H., Zhang, R., Yi, L., Tang, Y. & Zheng, C. UNC93B1 attenuates the cGAS-STING
756 signaling pathway by targeting STING for autophagy-lysosome degradation. *J. Med. Virol.* **94**,
757 4490-4501 (2022).
- 758 109. Ciężyńska, M. *et al.* The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis:
759 Review. *Int. J. Mol. Sci.* **22**, 5898. doi: 10.3390/ijms22115898 (2021).
- 760 110. Docherty, C. A. *et al.* A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the
761 treatment of inflammatory diseases. *Clin. Transl. Immunology* **12**, e1455 (2023).
- 762 111. Miyashita, Y. *et al.* TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-
763 mediated inflammatory responses. *Life. Sci. Alliance* **5**, e202101181. doi:
764 10.26508/lsa.202101181. Print 2022 Feb (2021).
- 765 112. Jensen, L. T., Attfield, K. E., Feldmann, M. & Fugger, L. Allosteric TYK2 inhibition:
766 redefining autoimmune disease therapy beyond JAK1-3 inhibitors. *EBioMedicine* **97**, 104840
767 (2023).
- 768 113. Gevezova, M. *et al.* Autistic spectrum disorder (ASD) - Gene, molecular and pathway
769 signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling,
770 and neurodevelopment. *Brain Behav. Immun. Health.* **30**, 100646 (2023).
- 771 114. Pollina, E. A. *et al.* A NPAS4-NuA4 complex couples synaptic activity to DNA repair.
772 *Nature* **614**, 732-741 (2023).
- 773 115. Zhou, X. *et al.* Integrating de novo and inherited variants in 42,607 autism cases identifies
774 mutations in new moderate-risk genes. *Nat. Genet.* **54**, 1305-1319 (2022).
- 775 116. Wilfert, A. B. *et al.* Recent ultra-rare inherited variants implicate new autism candidate risk
776 genes. *Nat. Genet.* **53**, 1125-1134 (2021).
- 777 117. Fu, J. M. *et al.* Rare coding variation provides insight into the genetic architecture and
778 phenotypic context of autism. *Nat. Genet.* **54**, 1320-1331 (2022).
- 779 118. Mueller, F. S. *et al.* Deficient DNA base-excision repair in the forebrain leads to a sex-
780 specific anxiety-like phenotype in mice. *BMC Biol.* **20**, 170-1 (2022).
- 781 119. Shen, X. *et al.* The role of Gadd45b in neurologic and neuropsychiatric disorders: An
782 overview. *Front. Mol. Neurosci.* **15**, 1021207 (2022).
- 783 120. Dileep, V. *et al.* Neuronal DNA double-strand breaks lead to genome structural variations
784 and 3D genome disruption in neurodegeneration. *Cell* **186**, 4404-4421.e20 (2023).

- 785 121. Yang, C. *et al.* Expression signature of inflammation-associated long non-coding RNAs in
786 adult-onset Still's disease. *Clin. Exp. Rheumatol.* **39 Suppl 132**, 67-74 (2021).
- 787 122. Jaber, S., Toufektchan, E., Lejour, V., Bardot, B. & Toledo, F. p53 downregulates the
788 Fanconi anaemia DNA repair pathway. *Nat. Commun.* **7**, 11091 (2016).
- 789 123. Rakotopare, J. & Toledo, F. p53 in the Molecular Circuitry of Bone Marrow Failure
790 Syndromes. *Int. J. Mol. Sci.* **24**, 14940. doi: 10.3390/ijms241914940 (2023).
- 791 124. Parvin, S. *et al.* ATM depletion induces proteasomal degradation of FANCD2 and
792 sensitizes neuroblastoma cells to PARP inhibitors. *BMC Cancer* **23**, 313-y (2023).
- 793 125. Ishiai, M. Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and
794 Monoubiquitination. *Genes (Basel)* **12**, 1763. doi: 10.3390/genes12111763 (2021).
- 795 126. Tammimies, K. Genetic mechanisms of regression in autism spectrum disorder. *Neurosci.*
796 *Biobehav. Rev.* **102**, 208-220 (2019).
- 797 127. Golla, S. & Sweeney, J. A. Corticosteroid therapy in regressive autism: Preliminary findings
798 from a retrospective study. *BMC Med.* **12**, 79-79 (2014).
- 799 128. Rossignol, D. A. & Frye, R. E. A Systematic Review and Meta-Analysis of Immunoglobulin
800 G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism
801 Spectrum Disorder. *J. Pers. Med.* **11**, 488. doi: 10.3390/jpm11060488 (2021).
- 802 129. Hopfner, K. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING
803 signalling. *Nat. Rev. Mol. Cell Biol.* **21**, 501-521 (2020).
- 804 130. Phelan, T., Little, M. A. & Brady, G. Targeting of the cGAS-STING system by DNA viruses.
805 *Biochem. Pharmacol.* **174**, 113831 (2020).
- 806 131. Fan, Y. M., Zhang, Y. L., Luo, H. & Mohamud, Y. Crosstalk between RNA viruses and DNA
807 sensors: Role of the cGAS-STING signalling pathway. *Rev. Med. Virol.* **32**, e2343 (2022).
- 808 132. Wang, C. *et al.* Ultrasound-responsive low-dose doxorubicin liposomes trigger
809 mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. *Nat.*
810 *Commun.* **14**, 3877-x (2023).
- 811 133. Kim, J., Kim, H. & Chung, J. H. Molecular mechanisms of mitochondrial DNA release and
812 activation of the cGAS-STING pathway. *Exp. Mol. Med.* **55**, 510-519 (2023).
- 813 134. West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response.
814 *Nature* **520**, 553-557 (2015).
- 815 135. Lammert, C. R. *et al.* AIM2 inflammasome surveillance of DNA damage shapes
816 neurodevelopment. *Nature* **580**, 647-652 (2020).
- 817 136. Dawson, R. E. *et al.* The cytosolic DNA sensor AIM2 promotes Helicobacter-induced
818 gastric pathology via the inflammasome. *Immunol. Cell Biol.* **101**, 444-457 (2023).

- 819 137. Vinuesa, C. G., Grenov, A. & Kassiotis, G. Innate virus-sensing pathways in B cell
820 systemic autoimmunity. *Science* **380**, 478-484 (2023).
- 821 138. Hu, Y. *et al.* Emerging role of the cGAS-STING signaling pathway in autoimmune
822 diseases: Biologic function, mechanisms and clinical prospection. *Autoimmun. Rev.* **21**, 103155
823 (2022).
- 824 139. Kivanc, D. & Dasdemir, S. The relationship between defects in DNA repair genes and
825 autoinflammatory diseases. *Rheumatol. Int.* **42**, 1-13 (2022).
- 826 140. Miner, J. J. & Fitzgerald, K. A. A path towards personalized medicine for autoinflammatory
827 and related diseases. *Nat. Rev. Rheumatol.* **19**, 182-189 (2023).
- 828 141. Li, R. *et al.* cGAS/STING signaling in the regulation of rheumatoid synovial aggression.
829 *Ann. Transl. Med.* **10**, 431-4533 (2022).
- 830 142. Hagiwara, A. M., Moore, R. E., Wallace, D. J., Ishimori, M. & Jefferies, C. A. Regulation of
831 cGAS-STING Pathway - Implications for Systemic Lupus Erythematosus. *Rheumatol. Immunol.*
832 *Res.* **2**, 173-184 (2021).
- 833 143. Wobma, H., Shin, D. S., Chou, J. & Dedeoğlu, F. Dysregulation of the cGAS-STING
834 Pathway in Monogenic Autoinflammation and Lupus. *Front. Immunol.* **13**, 905109 (2022).
- 835 144. Iourov, I. Y. *et al.* Causes and Consequences of Genome Instability in Psychiatric and
836 Neurodegenerative Diseases. *Mol. Biol. (Mosk)* **55**, 42-53 (2021).
- 837 145. Loncharich, M. F. & Anderson, C. W. Interferon Inhibition for Lupus with Anifrolumab:
838 Critical Appraisal of the Evidence Leading to FDA Approval. *ACR Open Rheumatol.* **4**, 486-491
839 (2022).
- 840 146. Weckerle, C. E. *et al.* Network analysis of associations between serum interferon- α activity,
841 autoantibodies, and clinical features in systemic lupus erythematosus. *Arthritis Rheum.* **63**,
842 1044-1053 (2011).
- 843 147. Nikolaidou, A., Beis, I., Dragoumi, P. & Zafeiriou, D. Neuropsychiatric manifestations
844 associated with Juvenile Systemic Lupus Erythematosus: An overview focusing on early
845 diagnosis. *Brain Dev.* (2023).
- 846 148. Van der Heijden, H. *et al.* Implications of Inflammatory Processes on a Developing Central
847 Nervous System in Childhood-onset Systemic Lupus Erythematosus. *Arthritis Rheumatol.*
848 (2023).
- 849 149. Ferecskó, A. S. *et al.* STING-Triggered CNS Inflammation in Human Neurodegenerative
850 Diseases. *Biomedicines* **11**, 1375. doi: 10.3390/biomedicines11051375 (2023).
- 851 150. Gulen, M. F. *et al.* cGAS-STING drives ageing-related inflammation and
852 neurodegeneration. *Nature* **620**, 374-380 (2023).

- 853 151. Chen, K. *et al.* cGAS-STING-mediated IFN-I Response in Host Defense and
854 Neuroinflammatory Diseases. *Curr. Neuropharmacol.* **20**, 362-371 (2022).
- 855 152. Beesetti, S. *et al.* FANCL supports Parkin-mediated mitophagy in a ubiquitin ligase-
856 independent manner. *Biochim. Biophys. Acta Mol. Basis Dis.* **1868**, 166453 (2022).
- 857 153. Luzwick, J. W. *et al.* MRE11-dependent instability in mitochondrial DNA fork protection
858 activates a cGAS immune signaling pathway. *Sci. Adv.* **7**, eabf9441 (2021).
- 859 154. Habibi, P. *et al.* Effect of heat stress on DNA damage: a systematic literature review. *Int. J.*
860 *Biometeorol.* **66**, 2147-2158 (2022).
- 861 155. Couillin, I. & Riteau, N. STING Signaling and Sterile Inflammation. *Front. Immunol.* **12**,
862 753789 (2021).
- 863 156. Yang, J. *et al.* STING in tumors: a focus on non-innate immune pathways. *Front. Cell. Dev.*
864 *Biol.* **11**, 1278461 (2023).
- 865 157. He, X. *et al.* IUPHAR ECR review: The cGAS-STING pathway: novel functions beyond
866 innate immune and emerging therapeutic opportunities. *Pharmacol. Res.*, 107063 (2024).
- 867 158. Xun, J. *et al.* A conserved ion channel function of STING mediates noncanonical
868 autophagy and cell death. *EMBO Rep.* (2024).

869

870 **Acknowledgments**

871 H.M.L. is supported by the National Institute of Child Health and Human Development
872 NIH/NICHD; P30 HD071593 to the Albert Einstein College of Medicine's Rose F. Kennedy
873 Intellectual and Developmental Disabilities Research Center, and the National Institute of
874 Mental Health, R21MH131740. The Lachman lab also receives support from the Janice C.
875 Blanchard Family Fund and the iPS Cell Research for Ryan Stearn Fund. This work was funded
876 by grants to the J.L.C Swedish Research Council (Grant No. 2019-06082). P.J. van der Spek is
877 supported by EU H2020 grants, an ImmunAID grant (ID: 7792950), and a
878 MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics infrastructure and team are
879 supported by grants from KWF, NWO/ZonMW, and the Dutch Heart Foundation through the
880 BDVA-initiated H2020 Bigmedilytics program on Personalized Medicine. Janet Cunningham is a
881 Gullstrand Fellow at Uppsala University Hospital. Jennifer Frankovich's research is supported
882 by several foundations including the Neuroimmune Foundation, Lucile Packard Foundation for
883 Children's Health, the Dollinger Biomarker Core, Stanford Spark, and collaborations on NIH
884 grants. Funders had no role in study design, data collection and analysis, decision to publish, or
885 preparation of the manuscript. We thank the Albert Einstein College of Medicine Epigenomics

886 Shared Core Facility RRID: SCR_023284 for Library preparation, QC, and sequencing, and
887 Yongmei Zhao for technical assistance with the library preps. The authors want to thank the
888 participating families.

889

890 **Author contributions**

891 J.L.C. co-wrote the paper, and was involved in the study concept and design; J.F. contributed
892 cases, provided genetic data for case 16, and co-wrote the manuscript); R,A.B. carried out
893 WES on case 10); E.P. processed DNA, validated variants, edited manuscript, created figures
894 1,3; R.F.A. validated variants; N.C.S. contributed case 16; S.B.M. made the WES library for
895 case 10; H.D. involved in study concept; J.M. validated variants); J.E. validated variants; J.M.S.
896 validated variants carried out Alphasense analysis; G.L. contributed case 1, edited
897 manuscript); S.M.A.S. bioinformatics of variants, created Figure 4; S.S. edited manuscript;
898 P.J.S. study concept and design, bioinformatics; H.M.L.co-wrote paper, study concept and
899 design, analyzed variants, confirmed diagnoses, supervised study. All authors reviewed the
900 manuscript.

901

902 **Data availability statement**

903 Variants reported in this paper will be submitted to ClinVar. WES data on case 10 will be made
904 available at GenBank ®

905

906 **Competing interests**

907 J.L.C. has received lecturing fees from Otsuka Pharma Scandinavia, Janssen-Cilag AB and H.
908 Lundbeck AB.

909

910 **Figure Legends**

911 **Figure 1. p53 DNA repair pathway.** A simplified depiction showing the regulation of p53 tumor
912 suppressor activity by phosphorylation triggered by ATM, ATR, CHK1, and CHK2 kinases, and
913 dephosphorylation by PPM1D. P53 activation can induce apoptosis or cell cycle arrest, which
914 will eliminate DNA-damaged cells or provide an opportunity to repair the damage, respectively.
915 Loss of function mutations in *ATM* or gain of function mutations in *PPM1D*, such as those found
916 in patients with acute neuropsychiatric decompensation in cases 1-7, would be expected to lead
917 to a decrease in p53 activity.

918 **Figure 2. Fanconi Core Complex.** The Fanconi Core Complex of proteins repairs interstrand
919 crosslink breaks (Figure adapted from reference 49). The letters are abbreviations for the

920 Fanconi complex proteins (i.e., “A” is FANCA; “E” is FANCE, etc.). Monoubiquitinated (Ub)
921 FANCD2 and FANCI form a dimer that binds to crosslink repair sites, which leads to the
922 recruitment of nucleases that repair the DNA lesion (reference 53). All of the Fanconi complex
923 genes described in this paper are depicted in bold type (FANCE, SLX4, FANCE, and FANCA).
924 Interactions between Fanconi proteins with ATM/ATR are shown. The image was generated
925 using biorender <https://www.biorender.com/>).

926 **Figure 3. Protein-Protein Interaction Network: STRING.** A connectivity network was
927 generated for the candidate genes using IPA software. Central to the network are ATM and p53.
928 Genes described in the paper that do not fit into the connectivity network are not shown (C7,
929 DBH, SLC13AS, SRPK3, NLRX1, MTO1, CACNA1H, CACNA1S, CLPB, AHNAK2). SLX4 =
930 FANCA/SLX4, TP53=p53, and TP53BP1 = 53BP1.

931 **Supplementary Data**

932 **Supplementary Methods.** An expanded description of the methods and primers used for
933 Sanger DNA sequencing.

934 **Supplementary Table.** Description of additional gene variants found upon whole exome
935 sequencing or the analysis of gene panels.


936 **Supplementary Figure. RMRP secondary structures.** The RNAfold web server was used to
937 predict secondary structures for wild-type and mutant (c. C126T) RMRP RNAs. Differences
938 between the two, especially in the centroid secondary structures, are seen.


939


Phosphorylation →
Dephosphorylation —|

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.20.24302984>; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

DNA Damage ⚡







| Case | Family | Age* | Gene | Dx | Variant | Type | CADD | ClinVar | AlphaMissense | Inheritance | MAF | Map position hg38 | rs number | Additional rare and ultrarare variants | Genome sequencing | validation |
|------|--------|----------|-------|----------------|------------------------------|--------------|-------|------------------------------|--------------------|-------------|---------|---------------------------|-------------|--|--|------------|
| 1 | N/A | 16-20 | PPM1D | JdVS, AR, PANS | c.1535delA, p.Asn5126Kfs | frameshift | N/A | pathogenic | N/A | de novo | 0.00002 | chr17:60663013 | rs763475304 | CSNK1a1, SRPB, SLC13A5, CACNA1S | GeneDx (WES) | yes |
| 2 | N/A | 6 to 10 | PPM1D | JdVS, AR | c.15736G>T, p.Glu525Ter | missense | 39 | uncertain significance | N/A | de novo | 7E-06 | chr17:60663307 | rs739930701 | none reported | NHS North West (NDD panel) | no |
| 3 | N/A | 11 to 15 | ATM | PANS | c.7517_7520del, p.Asp2506Pfs | frameshift | N/A | pathogenic | N/A | parent | 2E-06 | chr11:108343272-108343479 | rs87781905 | CACNA1H, AHNAK2 | Baylor Genetics (WES) | no |
| 4 | 1 | 6 to 10 | ATM | ASD, AR, PANS | c.8418-5_8418-8delG TGA | splice donor | N/A | pathogenic | N/A | parent | 4E-06 | chr11:108343272-108343479 | rs730881295 | RNASEH2B, RAG2, C7, NOD2, SP110 | Invitae (Immunodeficiency Panel) | yes |
| 5 | 1 | 11 to 15 | ATM | ASD, AR, PANS | c.8418-5_8418-8delG TGA | splice donor | N/A | pathogenic | N/A | parent | 4E-06 | chr11:108343272-108343479 | rs730881295 | RNASEH2B, RAG2, NOD2, [rs229640892] | Sanger sequencing of case 4 variants | yes |
| 6 | 1 | 6 to 10 | ATM | ASD, AR, PANS | c.8418-5_8418-8delG TGA | splice donor | N/A | pathogenic | N/A | parent | 4E-06 | chr11:108343272-108343479 | rs730881295 | RNASEH2B, C7, NOD2, [rs229640892] | GeneDx (WES) | yes |
| 7 | 1 | 6 to 10 | ATM | ASD, AR, PANS | c.8418-5_8418-8delG TGA | splice donor | N/A | pathogenic | N/A | parent | 4E-06 | chr11:108343272-108343479 | rs730881295 | RAG2, NOD2, [rs140716236], SP110 | Sanger sequencing of case 4 variants | yes |
| 8 | 2 | 0-5 | ATR | ASD, PANS AE | c.2507A>T, p.Asp936Val | missense | 24 | not found | benign, 0.095 | parent | unknown | chr3:142,553,850 | novel | CENPI, NLRX1, DBH, CACNA1S, CLPB | Invitae (Immunodeficiency Panel) | yes |
| 9 | 2 | 0-5 | ATR | ASD, PANS, AR | c.2507A>T, p.Asp936Val | missense | 24 | not found | benign, 0.095 | parent | unknown | chr3:142,553,850 | novel | CENPI, NLRX1, DBH, CACNA1S, CLPB | Courtagen Diagnostics Laboratory (WES) | yes |
| 10 | N/A | 0-5 | SBF1 | DD, AR, PANS | c.6330T>C, p.Asp1103Tyr | missense | 21.7 | not found | benign, 0.1176 | unknown | 0.00002 | chr15:83433462 | rs51138749 | MEI1, KMT2D, MTO1 | Emory Genetics Sibling Registry (WES) | yes |
| 11 | 3 | 0-5 | FANCF | CVID, PANS | c.127G>A, p.Gly43Ser | missense | 23.1 | uncertain significance | ambiguous, 0.4766 | parent | unknown | chr6:35452572 | rs92819655 | VPS13B | Invitae (Immunodeficiency Panel) | yes |
| 12 | 3 | 0-5 | FANCF | CVID, DD, AE | c.127G>A, p.Gly43Ser | missense | 23.1 | uncertain significance | ambiguous, 0.4766 | parent | unknown | chr6:35452572 | rs92819655 | VPS13B, THRAP3, NOD2 | Invitae (Immunodeficiency Panel) | yes |
| 13 | N/A | 11 to 15 | FANCI | AE, PANS | c.1461T>A, p.Tyr487Ter | missense | 37 | pathogenic/likely pathogenic | N/A | unknown | 0.00003 | chr15:89281149 | rs769248873 | FANCF/SLX4, LIG4 | Invitae (Immunodeficiency Panel) | no |
| 14 | 4 | 6 to 10 | FANCP | CVID, PANS, AE | c.2623 G>A, p.Glu875Lys | missense | 14.15 | not found | benign, 0.0771 | unknown | 1.6E-05 | chr16:3590914 | rs924446221 | RMRP, MEV, TNFRSF13B, DOC2B | Invitae (Immunodeficiency Panel) | no |
| 15 | 4 | 6 to 10 | FANCP | CVID, AE | c.2623 G>A, p.Glu875Lys | missense | 14.15 | not found | benign, 0.0771 | unknown | 1.6E-05 | chr16:3590914 | rs924446221 | RMRP, MEV, TNFRSF13B, DOC2B | Invitae (Immunodeficiency Panel) | no |
| 16 | N/A | 6 to 10 | FANCA | PANS | c.1771C>G, p.Arg916Gly | missense | 21.9 | uncertain significance | pathogenic, 0.6394 | unknown | 0.00006 | chr16:39778848 | rs753980264 | UNC93B1, NLRP1, TICAM1, TYK2, TCN2 | Invitae (Immunodeficiency and Cellular Dyskinesia Panel) | no |

Table. Description of all primary DNA repair variants. *Age range at diagnosis; Dx: diagnosis (JdVS: Jansen de Vries Syndrome, AR: acute regression, PANS: pediatric acute-onset neuropsychiatric syndrome, AE: autoimmune encephalitis, DD: developmental delay, CVID: common variable immune deficiency); variant shows the cDNA and amino acid changes; type shows how the mutation affects gene function; CADD: Combined Annotation score; N/A not available. ClinVar is the predicted pathogenicity based on the ClinVar database; AlphaMissense is the predicted pathogenicity based on amino acid change (see main text); Inheritance pattern shows that the variant in question was either de novo or transmitted from a parent. The sex of the parent was omitted to maintain anonymity; MAF: Minor allele frequency; Map position shows coordinates of variants based on hg38 build; rs number is based on SNP database; Additional variants were found in each case (see Supplemental table for descriptions); Genome sequencing shows the genetic analysis that was carried out; validation by Sanger sequencing